Item 5. Other Information
Item 5. Other Information.
None.
28
Table of Contents
Item 6. Exhibits.
The following exhibits are included in this Form 10-Q or incorporated herein by reference:
Exhibit No.
Exhibit Description
3.1
Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on February 28, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on February 8, 2022).
3.2
Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on April 12, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on March 8, 2022).
3.3
Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on November 3, 2022 (incorporated by reference to Annex A included in Exhibit 99.1 to Form 6-K filed with the SEC on September 21, 2022).
3.4
Amendment to the Amended and Restated Articles of Association of Quoin Pharmaceuticals Ltd., adopted on October 26, 2023 (incorporated by reference to Annex A included in the proxy statement filed with the SEC on September 12, 2023).
10.1
License and Distribution Agreement, by and between Quoin Pharmaceuticals Ltd. and Farma Mondo (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on September 13, 2023.(certain provisions of this exhibit have been omitted pursuant to Regulation S-K, Item 601(b)(10)(iv)).
31.1*
Certification of Chief Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934
31.2*
Certification of Chief Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934
32.1*
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350
32.2*
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350
101*
Information formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Shareholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
104*
Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)
* Filed herewith
29
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Quoin Pharmaceuticals Ltd.
November 9, 2023
By:
/s/ Gordon Dunn
Name: Gordon Dunn
Title: Chief Financial Officer
30
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.